Long-term safety and effectiveness of tanezumab 10 mg vs. 20 mg for chronic low back pain .
This study has been identified as potentially high impact.
OE's AI-driven High Impact metric estimates the influence a paper is likely to have by integrating signals from both the journal in which it is published and the scientific content of the article itself.
Developed using state-of-the-art natural language processing, the OE High Impact model more accurately predicts a study's future citation performance than journal impact factor alone.
This enables earlier recognition of clinically meaningful research and helps readers focus on articles most likely to shape future practice.
Long-term safety and effectiveness of tanezumab as treatment for chronic low back pain
Pain. 2014 Sep;155(9):1793-801.849 patients with chronic low back pain (equal or > 3 months) were randomized to receive three intravenous injections of 10 mg or 20 mg of tanezumab followed by up to 4 subcutaneous injections every 8 weeks. This extension study aimed to compare the long-term safety and effectiveness of two different tanezumab doses. Ten and 20 mg doses of tanezumab produced similar effectiveness outcomes at 24 weeks post-intervention, but tanezumab 20 mg had a higher overall incidence of adverse events. This trial was discontinued before it could reach its preplanned follow-up of 64 weeks due a temporary clinical hold being place on the drug by the FDA.
Unlock the Full ACE Report
You have access to 4 more FREE articles this month.
Click below to unlock and view this ACE Reports
Unlock Now
Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics